Scientist I, Quantitative Systems Pharmacologist
Revolution Medicines - Redwood City, California, United States
Posted May 8, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified
- Salary
- $119K-$149K not verified - source not recorded; timestamp not recorded
- 401(k) match
- Not verified
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $111,944 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +13.7% - Much faster than average
20% above the BLS role benchmark for data and ml aggregate.
Matched to SOC 15-1252 - Data and ML aggregate by role bucket.
Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Scientist I, Quantitative Systems Pharmacologist Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a QSP modeling & simulation scientist to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) organization. This position will be responsible for developing, validating, and executing modeling projects with a focus on mechanistic PBPK-QSP mathematical models for small molecule programs to increase mechanistic understanding of compound PK behavior and drug distribution, pharmacological effects on RAS targets, support clinical translation, and drive future discovery and development efforts. As a Quantitative Systems Pharmacologist, you will: - Develop, validate, execute, and refine quantitative systems pharmacology (QSP) models, minimal physiologically based pharmacokinetic (PBPK) models, semi-mechanistic PK/PD models, and tumor growth models to support development and discovery phase projects including next-generation inhibitor design and assessment of combination potential. - Propose and perform in silico simulations to answer complex mechanistic questions, create data visualizations to effectively communicate modeling results to a wide-ranging audience,
Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.
Apply link not verified; last-live date unavailable.
What verified means
Verified means a displayed claim has a recorded source field, a source URL when available, and a timestamp showing when FewerJobs checked or enriched the evidence.
Related jobs
-
Systems Engineer - (Execution) - Level 3/4
Northrop Grumman - United States-Alabama-Huntsville
-
Business Analyst (Top Secret cleared)
ICF International INC - Washington, DC
-
Engineering Project Specialist II (Full Time) - United State
Cisco - San Jose, California, US
-
Electrical Engineer 2
Northrop Grumman - United States-Alabama-Marshall Space Flight Center